Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib

BACKGROUND: Melanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, there have been no large studies examining the association...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Autores principales: Syeda, Mahrukh M, Wiggins, Jennifer M, Corless, Broderick C, Long, Georgina V, Flaherty, Keith T, Schadendorf, Dirk, Nathan, Paul D, Robert, Caroline, Ribas, Antoni, Davies, Michael A, Grob, Jean Jacques, Gasal, Eduard, Squires, Matthew, Marker, Mahtab, Garrett, James, Brase, Jan C, Polsky, David
Formato: Artigo
Lenguaje:Inglês
Publicado: 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034833/
https://ncbi.nlm.nih.gov/pubmed/33587894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30726-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares